The FDA cleared TriSalus’s TriNav Advance device, which extends the SmartValve-based drug delivery technology to improve tumor penetration during liver embolization.
|Videos|August 25, 2017
Impact of SOFT/TEXT in Premenopausal Breast Cancer
Author(s)Prudence A. Francis, MD
This video reviews the impact of the SOFT/TEXT trials for the treatment of patients with premenopausal breast cancer, and ways to best use the results.
Advertisement
In this video, Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre in Melbourne, reviews the impact of the SOFT/TEXT trials for the treatment of premenopausal breast cancer patients, and ways to best use the results.
Francis gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Advertisement
Related to this article
In the phase 1b CAMMA 1 trial, cevostamab plus pomalidomide and dexamethasone produced overall response rates of 86.2% to 88.0%.
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.
Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Daratumumab Combo Yields Responses in Cardiac-Involved AL Amyloidosis Trials
3
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
4
Epcoritamab Combo Receives Canadian Approval in R/R Follicular Lymphoma
5